A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

被引：45
|
作者：
Wu, Xiujuan [1 ]
Tang, Peng [1 ]
Li, Shifei [1 ]
Wang, Shushu [1 ]
Liang, Yueyang [1 ]
Zhong, Ling [1 ]
Ren, Lin [1 ]
Zhang, Ting [1 ]
Zhang, Yi [1 ]
机构：
[1] Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China
来源：
NATURE COMMUNICATIONS | 2018年 / 9卷
关键词：
PATHOLOGICAL COMPLETE RESPONSE; ARTERIAL CHEMOEMBOLIZATION; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; DOCETAXEL; CARBOPLATIN; EPIRUBICIN; PACLITAXEL; CISPLATIN; DOXORUBICIN;
D O I：
10.1038/s41467-018-03210-2
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.
引用
收藏
页数：8
相关论文
共 50 条
  • [11] A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)
    Parton, Marina
    Bardia, Aditya
    Kummel, Sherko
    Estevez, Laura G.
    Huang, Chiun-Sheng
    Castan, Javier Cortes
    Borrego, Manuel Ruiz
    Telli, Melinda L.
    Lluch, Ana
    Lopez, Rafael
    Beck, J. Thaddeus
    Ismail-Khan, Roohi
    Chen, Shin-Cheh
    Hurvitz, Sara A.
    Mayer, Ingrid A.
    Atienza, Rolando S.
    Cameron, Scott
    Krygowski, Mizue
    Kim, Sung-Bae
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [12] Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer
    Smith, John W., II
    McIntyre, Kristi J.
    Acevedo, Patrick V.
    Encarnacion, Carlos A.
    Tedesco, Karen L.
    Wang, Yunfei
    Asmar, Lina
    O'Shaughnessy, Joyce A.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 118 (02) : 361 - 367
  • [13] Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer
    John W. Smith
    Kristi J. McIntyre
    Patrick V. Acevedo
    Carlos A. Encarnacion
    Karen L. Tedesco
    Yunfei Wang
    Lina Asmar
    Joyce A. O’Shaughnessy
    Breast Cancer Research and Treatment, 2009, 118 : 361 - 367
  • [14] Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial.
    Zhang, Xiangmei
    Zhang, Shuo
    Li, Zhong
    Niu, Fengling
    Cai, Haifeng
    Li, Xianqiao
    Han, Meng
    Huang, Ruixue
    Liu, Yunjiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [15] Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
    Tanizaki, J.
    Yonemori, K.
    Akiyoshi, K.
    Minami, H.
    Ueda, H.
    Takiguchi, Y.
    Miura, Y.
    Segawa, Y.
    Takahashi, S.
    Iwamoto, Y.
    Kidera, Y.
    Fukuoka, K.
    Ito, A.
    Chiba, Y.
    Sakai, K.
    Nishio, K.
    Nakagawa, K.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 216 - 226
  • [16] Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer
    Clavarezza, Matteo
    Turazza, Monica
    Aitini, Enrico
    Saracchini, Silvana
    Garrone, Ornella
    Durando, Antonio
    De Placido, Sabino
    Bisagni, Giancarlo
    Levaggi, Alessia
    Bighin, Claudia
    Restuccia, Eleonora
    Scalamogna, Roberto
    Galli, Anna
    Del Mastro, Lucia
    BREAST, 2013, 22 (04): : 470 - 475
  • [17] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [18] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
  • [19] Neoadjuvant XELOX chemotherapy with or without cadonilimab in locally advanced pMMR rectal cancer: Preliminary results from a randomized, open-label phase II trial
    Zhou, H.
    Gong, C.
    Zhang, J.
    Zou, S.
    Tang, J.
    Liang, J.
    Liu, Z.
    Zhang, W.
    Jiang, Z.
    Qu, W.
    Zhang, H.
    Zhao, Q.
    Sun, Y.
    Zhou, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S104 - S104
  • [20] (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
    Reni, Michele
    Dugnani, Erica
    Cereda, Stefano
    Belli, Carmen
    Balzano, Gianpaolo
    Nicoletti, Roberto
    Liberati, Daniela
    Pasquale, Valentina
    Scavini, Marina
    Maggiora, Paola
    Sordi, Valeria
    Lampasona, Vito
    Ceraulo, Domenica
    Di Terlizzi, Gaetano
    Doglioni, Claudio
    Falconi, Massimo
    Piemonti, Lorenzo
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1076 - 1085
12345